Loading…
WAYMADE-MARAVIROC is a brand name for Maraviroc, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: WAYMADE-MARAVIROC (maraviroc), in combination with other antiretroviral agents, is indicated for adult patients infected with CCR5-tropic HIV-1. The following points should be considered when initiating therapy with WAYMADE-MARAVIROC: • CCR5 tropism should be confirmed using a highly sensitive tropism assay prior to…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations • Therapy should be initiated by a healthcare professional experienced in the management of HIV infection. • WAYMADE-MARAVIROC must be taken every day in combination with other antiretroviral agents. The recommended dose is 300 mg twice daily, but adjustments are recommended based on the patient’s concomitant medications.
WAYMADE-MARAVIROC can be taken with or without food. 2 Recommended Dose and Dosage Adjustment Adults The recommended dose of WAYMADE-MARAVIROC is 300 mg twice daily. A dose adjustment may be needed due to the potential for drug interactions (see Table 1 and 9 DRUG INTERACTIONS Drug-Drug Interactions, Table 8).
Table 1 Recommended Dosing Regimen Concomitant Medications Dose of WAYMADE- MARAVIROC Potent CYP3A4 inhibitors (with or without a CYP3A4 inducer) including, but not limited to: • protease inhibitors (except tipranavir/ritonavir) • delavirdine • ketoconazole, itraconazole, clarithromycin 150 mg twice daily Potent CYP3A4 inducers (without a potent CYP3A4 inhibitor) including, but not limited to: • efavirenz • rifampin • etravirine • carbamazepine, phenobarbital, and phenytoin 600 mg twice daily Other concomitant medications, including all other antiretrovirals that are not potent CYP3A4 inhibitors or potent CYP3A4 inducers, including tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide 300 mg twice daily Geriatrics (>65 years of age) There were insufficient numbers of subjects aged 65 and over in the clinical studies to determine whether they respond differently from younger subjects.
In general, caution should be exercised when administering WAYMADE-MARAVIROC in elderly patients, also reflecting the greater frequency of decreased hepatic and renal function, of concomitant disease and other drug therapy. Pediatrics (<18 years of age) The pharmacokinetics, safety and efficacy of maraviroc in pediatric patients have not been established.
Therefore, maraviroc should not be used in this patient population. WAYMADE-MARAVIROC Page 6 of 56 Renal Insufficiency WAYMADE-MARAVIROC should not be used in patients with severe renal impairment or ESRD (CLcr < 30 mL/min) who are taking potent CYP3A inhibitors or inducers (see 7 WARNINGS AND PRECAUTIONS).
No dose adjustment is necessary for renally impaired patients, including patients with ESRD, requiring dialysis, not receiving a potent CYP3A4 inhibitor in combination with WAYMADE-MARAVIROC. Table 2 below provides dosing interval adjustment guidelines for patients based on renal function and concomitant medications.
). 1 Dosing Considerations • Therapy should be initiated by a healthcare professional experienced in the management of HIV infection. • WAYMADE-MARAVIROC must be taken every day in combination with other antiretroviral agents. The recommended dose is 300 mg twice daily, but adjustments are recommended based on the patient’s concomitant medications.
WAYMADE-MARAVIROC can be taken with or without food. 2 Recommended Dose and Dosage Adjustment Adults The recommended dose of WAYMADE-MARAVIROC is 300 mg twice daily. A dose adjustment may be needed due to the potential for drug interactions (see Table 1 and
4 Geriatrics). 2 CONTRAINDICATIONS WAYMADE-MARAVIROC is contraindicated in patients with hypersensitivity to maraviroc or any component of this medication. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING of this product monograph.
3 SERIOUS WARNINGS AND PRECAUTIONS BOX Serious Warnings and Precautions Hepatotoxicity has been reported with maraviroc tablets use. A systemic allergic reaction, including pruritic rash, eosinophilia or elevated IgE may occur prior to the development of hepatotoxicity.
Patients with signs or symptoms of acute hepatitis or allergic reaction should be evaluated immediately and, if required, discontinuation of WAYMADE-MARAVIROC treatment should be strongly considered. (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic and
WAYMADE-MARAVIROC is contraindicated in patients with hypersensitivity to maraviroc or any component of this medication. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING of this product monograph.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Maraviroc in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Table 2 Dose and interval adjustments for patients with renal impairment Concomitant Medications Dose of WAYMADE-MARAVIROC Based on Renal Function Normal (CLcr >80 mL/min) Mild (CLcr >50 and ≤ 80 mL/min) Moderate (CLcr ≥ 30 and ≤ 50 mL/min) Severe (CLcr <30 mL/min) End Stage Renal Disease (ESRD) Potent CYP3A inhibitors (with or without a CYP3A inducer) including: • protease inhibitors (except tipranavir/ritonavir) • delavirdine • ketoconazole, itraconazole, clarithromycin • other potent CYP3A inhibitors 150 mg twice daily 150 mg twice daily 150 mg twice daily NR NR Potent CYP3A inducers (without a potent CYP3A inhibitor) including: • efavirenz • rifampin • etravirine • carbamazepine, phenobarbital, phenytoin 600 mg twice daily 600 mg twice daily 600 mg twice daily NR NR Other concomitant medications, including: • tipranavir/ritonavir • nevirapine • raltegravir • all NRTIs • enfuvirtide 300 mg twice daily 300 mg twice daily 300 mg twice daily 300 mg twice dailya 300 mg twice dailya NR=Not recommended a The dose of WAYMADE-MARAVIROC should be reduced to 150 mg twice daily if there are any symptoms of postural hypotension (see 7 WARNINGS AND PRECAUTIONS).
5 Missed Dose If a dose is missed, patients should take the next dose as soon as possible. A dose should not be doubled.